Tongxinluo capsule has three protective effects-blood protection, blood vessel protection and ischemic heart and brain tissue protection.
The original research of a major theoretical prescription —— "Research on Tongxinluo Capsule in Treating Coronary Heart Disease" won the second prize of National Science and Technology Progress Award in 2000.
Modern ultrafine grinding pharmaceutical technology-"Insect medicine ultrafine powder technology and its application" won the second prize of national technological invention in 2007.
Shen Song Yangxin Capsule
Patented new drug for arrhythmia
The research shows that Shen Song Yangxin Capsule can obviously improve the influence of load increase before and after, promote the improvement of cardiac function, inhibit atrial and ventricular electrical remodeling, play an antiarrhythmic role, reduce nerve fiber density after myocardial infarction, and inhibit nerve remodeling after myocardial infarction, showing the systematic effect of "treating both symptoms and root causes slowly, integrating and regulating" arrhythmia.
Medicine for treating arrhythmia with comprehensive regulation function of multi-ion channel and non-ion channel
"Research on Shen Song Yangxin Capsule in Treating Arrhythmia" won the second prize of National Science and Technology Progress Award in 2009.
Qili Qiangxin Capsules
Qiliqiangxin capsule has the functions of strengthening heart, diuresis, dilating blood vessels, improving hemodynamics and quickly relieving symptoms of heart failure.
Innovative Chinese medicine cited in the guidelines for diagnosis and treatment of heart failure of Chinese Medical Association.
With the support of the National 863 Program, Qiliqiangxin Capsule was successfully developed, which brought new hope for the drug treatment of patients with chronic heart failure. Clinical evidence-based research papers were published in the international authoritative journal JACC, and extensive experimental research revealed the therapeutic mechanism of the drug. The great attention of the international medical community shows its important clinical value and broad market prospect in the treatment of chronic heart failure.
Lianhua Qingwen capsule
The research of Lianhua Qingwen in treating influenza won the second prize of National Science and Technology Progress Award 20 1 1.
Based on the collateral disease theory, this paper discusses the pathogenesis and treatment of influenza in traditional Chinese medicine, and puts forward the strategy of "active intervention". Combining Maxing Shigan Decoction from Treatise on Febrile Diseases in Han Dynasty, Dahuang from Plague Theory in Ming Dynasty and Yinqiao Powder from Epidemic Febrile Diseases in Qing Dynasty, it is particularly effective in treating early symptoms of cold and influenza, and has broad-spectrum antiviral, antibacterial, anti-inflammatory and antipyretic effects, expectorant and antitussive effects.